Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

RNA−binding protein FXR1 stabilizes receptor tyrosine kinase FGFR1 and enhances PI3K−Akt signaling to promote T−cell leukemogenesis

Boxiao Chen, Zhaoxing Wu, Luyu Yang, Yang Xu

Blood (2025) 146 (Supplement 1): 5039.

https://doi.org/10.1182/blood-2025-5039

Published: 2025

Journal Articles

Efficacy and safety of the TEAM conditioning for autologous stem cell transplantation in lymphoma patients with high-risk of central nervous system relapse

Xi Qiu, Huawei Jiang, Zhaoxing Wu, Boxiao Chen, Luyu Yang, Yang Xu

Blood (2025) 146 (Supplement 1): 5454.

https://doi.org/10.1182/blood-2025-5454

Published: 2025

Journal Articles

Hesperadin, an aurora B kinase inhibitor, synergizes with chidamide to suppress T-cell acute lymphoblastic leukemia by targeting c-MYC

Boxiao Chen, Zhaoxing Wu, Luyu Yang, Yang Xu

Blood (2025) 146 (Supplement 1): 6828.

https://doi.org/10.1182/blood-2025-6828

Published: 2025

Journal Articles

Relationship between myeloma cell genomic alternations and tumor immune microenvironment in bone-related extramedullary disease of newly diagnosed multiple myeloma

Wenbin Qian, Xuzhao Zhang, Yang Xu, Yun Liang

Blood (2025) 146 (Supplement 1): 5722.

https://doi.org/10.1182/blood-2025-5722

Published: 2025

Journal Articles

Neutrophil count is an independent prognostic indicator in early T-cell precursor lymphoblastic leukemia

Jieping Lin, Xiaoyuan Gong, Nanfang Zhuo, Chengming He, Yiming Cai, Zhixiang Wang, Xuan Zhou, Bailin He, Wenhao Zhong, Qifa Liu, Suning Chen, Yang Xu, Huafeng Wang, Ying Wang, Hongsheng Zhou

Blood (2025) 146 (Supplement 1): 6892.

https://doi.org/10.1182/blood-2025-6892

Published: 2025

Journal Articles

Chemo-free regimen based on venetoclax and azacytidine as induction therapy for adults with newly-diagnosed mixed phenotype acute leukemia

Jia Chen, Ying Zhang, Yi Fan, Mimi Xu, Shengli Xue, Xiaowen Tang, Miao Miao, Huiying Qiu, Suning Chen, Yang Xu, Xiang Zhang, Huanle Gong, Depei Wu

Blood (2025) 146 (Supplement 1): 6904.

https://doi.org/10.1182/blood-2025-6904

Published: 2025

Journal Articles

Efficacy of a venetoclax-based, anthracycline-free regimen in newly diagnosed CBFβ::MYH11(+) acute myeloid leukemia

Ziyu Feng, Jia Chen, Haiping Dai, Xiaohui Hu, Yang Xu, Shengli Xue, Huiying Qiu, Xiaowen Tang, Han Yue, Suning Chen, Depei Wu, Ying Wang

Blood (2025) 146 (Supplement 1): 1674.

https://doi.org/10.1182/blood-2025-1674

Published: 2025

Journal Articles

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

Blood (2025) 145 (22): 2645–2655.

https://doi.org/10.1182/blood.2024027217

Published: 2025

Includes: Supplemental data

Journal Articles

The hepcidin-ferroportin axis modulates liver endothelial cell BMP expression to influence iron homeostasis in mice

Allison L. Fisher, Sydney Phillips, Chia-Yu Wang, Joao A. Paulo, Xia Xiao, Yang Xu, Gillian A. Moschetta, Yongqiang Xue, Joseph D. Mancias, Jodie L. Babitt

Blood (2025) 145 (6): 625–634.

https://doi.org/10.1182/blood.2024024795

Published: 2025

Includes: Supplemental data

Journal Articles

YAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia

Shuhong Hu, Yifei Liu, Xiang Zhang, Xiaoqi Wang, Yanting Li, Mengqian Chu, Jie Yin, Yanglan Fang, Changgeng Ruan, Li Zhu, Depei Wu, Yang Xu

Blood (2024) 144 (20): 2136–2148.

https://doi.org/10.1182/blood.2023023601

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Venetoclax in Combination with Hypomethylating Agents for the Treatment of High-Risk Myelodysplastic Syndromes–Real-World Analyses

Jian Zhang, Yang Xu, Zhihong Lin, Jun Chen, Limin Liu, Depei Wu, Huiying Qiu

Blood (2024) 144 (Supplement 1): 6732.

https://doi.org/10.1182/blood-2024-199990

Published: 2024

Journal Articles

Large-Scale Metabolomic Mendelian Randomization Analysis Identifies Pyridoxate As a Key Factor in Graft-Versus-Host Disease

Xinghao Yu, Yiyin Chen, Lei Lei, Dandan Lin, Ying Shen, Chang Hou, Jia Chen, Yi Fan, Huimin Lu, Depei Wu, Yang Xu

Blood (2024) 144 (Supplement 1): 3523.

https://doi.org/10.1182/blood-2024-206745

Published: 2024

Journal Articles

Real-World Data of Maintenance Therapy for Newly Diagnosed Multiple Myeloma: Ixazomib Versus Lenalidomide

Yang Xu, Xuzhao Zhang, Luyao Wang, Yili Fan, Boxiao Chen, Luyu Yang, Jiawei Zhang

Blood (2024) 144 (Supplement 1): 3792.3.

https://doi.org/10.1182/blood-2024-205549

Published: 2024

Journal Articles

Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBFβ::MYH11(+) Acute Myeloid Leukemia

Ziyu Feng, Xiaohui Hu, Weiyang Li, Ting Xu, Yang Xu, Shengli Xue, Huiying Qiu, Xiaowen Tang, Yue Han, Suning Chen, Aining Sun, Depei Wu, Ying Wang

Blood (2024) 144 (Supplement 1): 4287.

https://doi.org/10.1182/blood-2024-198648

Published: 2024

Journal Articles

Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 2171.

https://doi.org/10.1182/blood-2024-212040

Published: 2024

Journal Articles

Subcutaneous Abatacept for Acute Graft-Versus-Host Disease Prophylaxis after Haploidentical Donor Hematopoietic Cell Transplantation: Efficacy, Safety, and Immunologic Effects

Yuhua Ru, Jinjin Zhu, Huanle Gong, Mimi Xu, Ying Wang, Miao Miao, Suning Chen, Xiang Zhang, Yi Fan, Yang Xu, Jia Chen, Depei Wu

Blood (2024) 144 (Supplement 1): 3515.

https://doi.org/10.1182/blood-2024-202490

Published: 2024

Journal Articles

Autologous Fecal Microbiota Transplantation As a Gvhd Prophylaxis in Patients with Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Trial

Yin Liu, Ye Zhao, Xiaofei Qi, Qiao Cheng, Jia Chen, Xiao Ma, Shengli Xue, Ying Wang, Xiaowen Tang, Huiying Qiu, Yang Xu, Depei Wu

Blood (2024) 144 (Supplement 1): 3535.

https://doi.org/10.1182/blood-2024-209696

Published: 2024

Journal Articles

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Jieping Lin, Chenhao Ding, Zicong Huang, Cai Zihong, Jia Li, Zhixiang Wang, Xiaofang Li, Xuan Zhou, Bailin He, Wenhao Zhong, Li Xuan, Qifa Liu, Yang Xu, Hongsheng Zhou

Blood (2024) 144 (Supplement 1): 839.

https://doi.org/10.1182/blood-2024-200513

Published: 2024

Journal Articles

BEAT Chemofree Regimen for Relapsed/Refractory and De Novo T-ALL

Jieping Lin, Xuan Zhou, Zhixiang Wang, Dainan Lin, Yu Zhan, Zan Li, Jiwei Huang, Yonghua Li, Xudong Ma, Qifa Liu, Li Xuan, Yang Xu, Hongsheng Zhou

Blood (2024) 144 (Supplement 1): 5901.

https://doi.org/10.1182/blood-2024-203250

Published: 2024

Journal Articles

Early Responders (Time to Best Response ≤3 months) Predicts Functional High-Risk Multiple Myeloma

Yang Xu, Yili Fan, Luyao Wang, Jiawei Zhang, Boxiao Chen, Luyu Yang, Xuzhao Zhang

Blood (2024) 144 (Supplement 1): 3345.

https://doi.org/10.1182/blood-2024-205449

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

RNA−binding protein FXR1 stabilizes receptor tyrosine kinase FGFR1 and enhances PI3K−Akt signaling to promote T−cell leukemogenesis

Efficacy and safety of the TEAM conditioning for autologous stem cell transplantation in lymphoma patients with high-risk of central nervous system relapse

Hesperadin, an aurora B kinase inhibitor, synergizes with chidamide to suppress T-cell acute lymphoblastic leukemia by targeting c-MYC

Relationship between myeloma cell genomic alternations and tumor immune microenvironment in bone-related extramedullary disease of newly diagnosed multiple myeloma

Neutrophil count is an independent prognostic indicator in early T-cell precursor lymphoblastic leukemia

Chemo-free regimen based on venetoclax and azacytidine as induction therapy for adults with newly-diagnosed mixed phenotype acute leukemia

Efficacy of a venetoclax-based, anthracycline-free regimen in newly diagnosed CBFβ::MYH11(+) acute myeloid leukemia

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

The hepcidin-ferroportin axis modulates liver endothelial cell BMP expression to influence iron homeostasis in mice

YAP1 regulates thrombopoiesis by binding to MYH9 in immune thrombocytopenia

Efficacy and Safety of Venetoclax in Combination with Hypomethylating Agents for the Treatment of High-Risk Myelodysplastic Syndromes–Real-World Analyses

Large-Scale Metabolomic Mendelian Randomization Analysis Identifies Pyridoxate As a Key Factor in Graft-Versus-Host Disease

Real-World Data of Maintenance Therapy for Newly Diagnosed Multiple Myeloma: Ixazomib Versus Lenalidomide

Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBFβ::MYH11(+) Acute Myeloid Leukemia

Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Subcutaneous Abatacept for Acute Graft-Versus-Host Disease Prophylaxis after Haploidentical Donor Hematopoietic Cell Transplantation: Efficacy, Safety, and Immunologic Effects

Autologous Fecal Microbiota Transplantation As a Gvhd Prophylaxis in Patients with Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Trial

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

BEAT Chemofree Regimen for Relapsed/Refractory and De Novo T-ALL

Early Responders (Time to Best Response ≤3 months) Predicts Functional High-Risk Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only